477 related articles for article (PubMed ID: 27783452)
1. Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder.
Chen H; Qiu W; Zhang Q; Wang J; Shi Z; Liu J; Lian Z; Feng H; Miao X; Zhou H
Eur J Neurol; 2017 Jan; 24(1):219-226. PubMed ID: 27783452
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of effect of empirical attack-preventive immunotherapies in neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
Ma J; Yu H; Wang H; Zhang X; Feng K
J Neuroimmunol; 2022 Feb; 363():577790. PubMed ID: 34959021
[TBL] [Abstract][Full Text] [Related]
3. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and cyclophosphamide among patients with neuromyelitis optica spectrum disorder: A prospective cohort study.
Xu Y; Wang Q; Ren HT; Qiao L; Zhang Y; Fei YY; Zhao Y; Cui LY
J Neurol Sci; 2016 Nov; 370():224-228. PubMed ID: 27772764
[TBL] [Abstract][Full Text] [Related]
4. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder.
Yang Y; Wang CJ; Wang BJ; Zeng ZL; Guo SG
J Neurol Sci; 2018 Feb; 385():192-197. PubMed ID: 29406904
[TBL] [Abstract][Full Text] [Related]
5. The Efficacy and Tolerability of Mycophenolate Mofetil in Treating Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder in Western China.
Chen H; Zhang Y; Shi Z; Feng H; Yao S; Xie J; Zhou H
Clin Neuropharmacol; 2016; 39(2):81-7. PubMed ID: 26818042
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of azathioprine, mycophenolate mofetil, and rituximab in the treatment of neuromyelitis optica spectrum disorder and analysis of prognostic factors.
Zhang L; Tian J; Dong X; Jia Z; Sun Y; Guo L; Tan G; Li B
Neurol Sci; 2022 Apr; 43(4):2651-2658. PubMed ID: 34585292
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of modified reduced-dose rituximab in Chinese patients with neuromyelitis optica spectrum disorder: A retrospective cohort study.
Cao S; Yu H; Tian J; Li Y; Shen Y; Ji X; Wang X; Zhou X; Gu Y; Zhu F; Duan X; Xiao X; Fang Q; Chen X; Xue Q
J Neurol Sci; 2021 Oct; 429():117616. PubMed ID: 34450520
[TBL] [Abstract][Full Text] [Related]
8. Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder.
Huh SY; Kim SH; Hyun JW; Joung AR; Park MS; Kim BJ; Kim HJ
JAMA Neurol; 2014 Nov; 71(11):1372-8. PubMed ID: 25199960
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of azathioprine, mycophenolate mofetil, and reduced dose of rituximab in neuromyelitis optica spectrum disorder.
Huang W; Wang L; Xia J; Li W; Wang M; Yu J; Li Q; Wang B; Pan J; Du L; Ma J; Tan H; Chang X; Lu C; Zhao C; Lu J; Zhou L; ZhangBao J; Quan C;
Eur J Neurol; 2022 Aug; 29(8):2343-2354. PubMed ID: 35398950
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: A systematic review and meta-analysis.
Espiritu AI; Pasco PMD
Mult Scler Relat Disord; 2019 Aug; 33():22-32. PubMed ID: 31136907
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of rituximab versus oral immunosuppressive therapies in neuromyelitis optica spectrum disorder in a racially diverse cohort of subjects: A single-center retrospective study.
Dresser L; Chaar WA; Reder AT; Abuaf AF; Cipriani VP; Javed A
Mult Scler Relat Disord; 2023 Jun; 74():104718. PubMed ID: 37086634
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of mycophenolate mofetil in Thai neuromyelitis optica spectrum disorder patients.
Pathomrattanapiban C; Tisavipat N; Jitprapaikulsan J; Prayoonwiwat N; Rattanathamsakul N; Siritho S
Mult Scler Relat Disord; 2022 Jul; 63():103882. PubMed ID: 35598463
[TBL] [Abstract][Full Text] [Related]
13. Effects of immunotherapies and prognostic predictors in neuromyelitis optica spectrum disorder: a prospective cohort study.
Shi Z; Du Q; Chen H; Zhang Y; Qiu Y; Zhao Z; Wang J; Yan C; Zhang Q; Yang M; Zhou H
J Neurol; 2020 Apr; 267(4):913-924. PubMed ID: 31776721
[TBL] [Abstract][Full Text] [Related]
14. Predictors of azathioprine and mycophenolate mofetil response in patients with neuromyelitis optica spectrum disorder: A cohort study.
San Martin DL; Fukuda TG; Nascimento TS; Silva MB; Filho MBP; Forcadela M; Rocchi C; Gibbons E; Hamid S; Huda S; Oliveira-Filho J
Mult Scler Relat Disord; 2024 Mar; 83():105452. PubMed ID: 38277981
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of efficacy and tolerability of first-line therapies in NMOSD.
Poupart J; Giovannelli J; Deschamps R; Audoin B; Ciron J; Maillart E; Papeix C; Collongues N; Bourre B; Cohen M; Wiertlewski S; Outteryck O; Laplaud D; Vukusic S; Marignier R; Zephir H;
Neurology; 2020 Apr; 94(15):e1645-e1656. PubMed ID: 32170036
[TBL] [Abstract][Full Text] [Related]
16. Dose effects of mycophenolate mofetil in Chinese patients with neuromyelitis optica spectrum disorders: a case series study.
Jiao Y; Cui L; Zhang W; Zhang C; Zhang Y; Zhang X; Jiao J
BMC Neurol; 2018 Apr; 18(1):47. PubMed ID: 29688841
[TBL] [Abstract][Full Text] [Related]
17. Effective Rituximab Treatment in Patients with Neuromyelitis Optica Spectrum Disorders Compared with Azathioprine and Mycophenolate.
Yang Y; Chen L; Wu L; Yao J; Wang N; Su X; Li D; Han L; Wu W; Huang D; Jiang T; Wang Z
Neurol Ther; 2022 Mar; 11(1):137-149. PubMed ID: 34797551
[TBL] [Abstract][Full Text] [Related]
18. Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica.
Costanzi C; Matiello M; Lucchinetti CF; Weinshenker BG; Pittock SJ; Mandrekar J; Thapa P; McKeon A
Neurology; 2011 Aug; 77(7):659-66. PubMed ID: 21813788
[TBL] [Abstract][Full Text] [Related]
19. Different monoclonal antibodies and immunosuppressants administration in patients with neuromyelitis optica spectrum disorder: a Bayesian network meta-analysis.
Yin Z; Qiu Y; Duan A; Fang T; Chen Z; Wu J; Wang Z; Chen G
J Neurol; 2023 Jun; 270(6):2950-2963. PubMed ID: 36884069
[TBL] [Abstract][Full Text] [Related]
20. Predictors of response to first-line immunosuppressive therapy in neuromyelitis optica spectrum disorders.
Kim SH; Hyun JW; Joung A; Park EY; Joo J; Kim HJ
Mult Scler; 2017 Dec; 23(14):1902-1908. PubMed ID: 28080220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
